A critically drug-resistant strain of gonorrhoea dubbed a “super-superbug” has been detected in every Australian state and territory by a new national surveillance system.
The National Alert System for Critical Antimicrobial Resistance (CARAlert) identified 1,064 bacteria highly resistant to last-line antibiotics between 17 March 2016 and 31 March 2017 across 73 laboratories.
Every day, more than 1 million sexually transmitted infections are acquired worldwide, and each year an estimated 78 million people are infected with gonorrhoea. New data from 77 countries show that antibiotic resistance is making gonorrhoea much harder – and sometimes impossible – to treat.
The data has been published in PLOS, in two new scientific articles.
The Lancet Infectious Diseases, 17 (2), February 2017
Antimicrobial resistance in Neisseria gonorrhoeae is recognised globally as a public health threat. Dual therapy with ceftriaxone and azithromycin has been introduced in Australia and elsewhere as the first-line treatment recommendation for gonorrhoea. While there have been only sporadic reports of ceftriaxone-resistant gonococci, globally there have been increasing reports of N gonorrhoeae resistance to azithromycin.1 The Australian Gonococcal Surveillance Programme2 is one of the most comprehensive N gonorrhoeae antimicrobial resistance surveillance programmes worldwide.
SImplification of an antiretroviral treatment to a boosted protease inhibitor and the nucleoside analogue lamivudine (a dual regimen) is highly effective in people switching from a stable three-drug regimen,researchers reported on Monday at theInternational Congress on Drug Therapy in HIV Infection (HIV Glasgow).